You are here

Article Text

Article menu
Download PDFPDF
Treatment
Review: inhaled corticosteroids increase risk of oral candidiasis, dysphonia, and pharyngitis in persistent asthma

https://doi.org/10.1136/ebn.10.4.109

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol 2007;98:225–38.OpenUrlPubMedWeb of Science

    Q Do inhaled corticosteroids increase risk of oral candidiasis, dysphonia, and pharyngitis in patients with persistent asthma?

    METHODS

    Embedded ImageData sources:

    Medline (January 1966 to June 2004) and EMBASE/Excerpta Medica (January 1974 to June 2004).

    Embedded ImageStudy selection and assessment:

    randomised, placebo controlled trials (RCTs) that evaluated oral inhaled corticosteroids (low dose <400 μg/d, medium dose 401–499 μg/d, or high dose ⩾1000 μg/d) alone or in combination in adults and adolescents with persistent asthma and reported incidence of oral candidiasis, dysphonia, or pharyngitis. Studies of patients who had chronic obstructive pulmonary disease were excluded. 23 RCTs met the selection criteria. The inhaled corticosteroids evaluated were fluticasone propionate (19 arms; 13 dry powder inhaler [DPI], 6 metered dose inhaler [MDI]), triamcinolone acetonide (8 arms; all MDI), budesonide (10 arms; 8 DPI, 2 MDI), beclomethasone dipropionate (11 arms; all MDI), and mometasone furoate (11 arms; 8 …

    View Full Text

    Footnotes

    • For correspondence: Dr G S Rachelefsky, Allergy Research Foundation Inc, Los Angeles, CA, USA. rachruss{at}ix.netcom.com

    • Sources of funding: Sanofi-Aventis US and ALTANA Pharma US.